I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Traumatic Brain Injury and Psychological Health Research Program

Translational Research Award

Announcement Type: Modified

Funding Opportunity Number: W81XWH-21-TBIPHRP-TRA

Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), November 1, 2021
- Invitation to Submit an Application: November 5, 2021
- Application Submission Deadline: 11:59 p.m. ET, December 16, 2021
- End of Application Verification Period: 5:00 p.m. ET, December 21, 2021
- Peer Review: February 2022
- Programmatic Review: April 2022

This program announcement must be read in conjunction with the General Application Instructions, version 605. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”
# TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY ................................................................. 1

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY .................. 3

   II.A. Program Description ............................................................................................... 3

   II.A.1. FY21 TBIPHRP TRA Focus Areas ___________________________________________ 3

   II.B. Award Information .................................................................................................. 8

   II.C. Eligibility Information ........................................................................................... 16

      II.C.1. Eligible Applicants ......................................................................................... 16

      II.C.2. Cost Sharing .................................................................................................... 17

      II.C.3. Other ............................................................................................................... 17

   II.D. Application and Submission Information .............................................................. 17

      II.D.1. Address to Request Application Package ....................................................... 18

      II.D.2. Content and Form of the Application Submission ........................................... 18

      II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM) ......................................... 44

      II.D.4. Submission Dates and Times .......................................................................... 45

      II.D.5. Funding Restrictions ....................................................................................... 46

      II.D.6. Other Submission Requirements .................................................................. 47

   II.E. Application Review Information ............................................................................ 48

      II.E.1. Criteria ............................................................................................................. 48

      II.E.2. Application Review and Selection Process ..................................................... 53

      II.E.3. Integrity and Performance Information .......................................................... 53

      II.E.4. Anticipated Announcement and Federal Award Dates ................................ 54

   II.F. Federal Award Administration Information ........................................................ 54

      II.F.1. Federal Award Notices ................................................................................... 54

      II.F.2. Administrative and National Policy Requirements ......................................... 55

      II.F.3. Reporting ......................................................................................................... 56

   II.G. Federal Awarding Agency Contacts .................................................................... 56

      II.G.1. CDMRP Help Desk ....................................................................................... 56

      II.G.2. Grants.gov Contact Center ............................................................................ 57

   II.H. Other Information ................................................................................................ 57

      II.H.1. Program Announcement and General Application Instructions Versions ...... 57

      II.H.2. Administrative Actions .................................................................................. 57

      II.H.3. Application Submission Checklist ................................................................ 60

APPENDIX 1: ACRONYM LIST .......................................................................................... 62

APPENDIX 2: DOD AND VA WEBSITES ....................................................................... 64

APPENDIX 3: SAMPLE FITBIR CONSENT LANGUAGE ................................................ 66
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2021 (FY21) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

In FY07, Congress appropriated funding for traumatic brain injury (TBI) and psychological health research in response to the traumatic brain injuries sustained and psychological health issues experienced by our deployed forces in Iraq and Afghanistan. The current Peer-Reviewed TBIPHRP complements ongoing Department of Defense (DOD) efforts toward promoting a better standard of care for psychological health and TBI in the areas of prevention, detection, diagnosis, treatment, and rehabilitation. Appropriations for the TBIPHRP from FY07 through FY20 totaled $1.872 billion (B). The FY21 appropriation is $175 million (M).

The TBIPHRP vision is to optimize psychological health and reduce or eliminate the effects of TBI and traumatic stress. The program seeks to fund research to understand, prevent, and treat TBI and psychological health conditions that accelerates solutions to improve the health, well-being, and healthcare of Service Members, Veterans, military beneficiaries, and the American public.

In April 2021, the TBIPHRP held a Stakeholders Meeting to engage traumatic brain injury and psychological health academic, clinical, lived experience (consumers), and government subject matter experts in an open dialogue forum to identify critical issues and underfunded areas in TBI and psychological health research and care. This meeting was attended by representatives from non-profit organizations, academia, government agencies, and the public. Outcomes from this meeting were considered by the TBIPHRP Programmatic Panel in developing the FY21 program. The FY21 Stakeholders Booklet and Meeting Summary, including presentation materials, can be found at https://cdmrp.army.mil/tbiphrp/.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

II.A.1. FY21 TBIPHRP TRA Focus Areas

To meet the intent of the FY21 TBIPHRP Translational Research Award (TRA), applications must address at least one sub-area within one of the three FY21 TBIPHRP TRA Focus Areas listed below. Selection of the appropriate FY21 TBIPHRP TRA Focus Area is the responsibility of the applicant.
1. **Understand**: Research will address knowledge gaps in foundational science, epidemiology, and etiology of TBI and psychological health.

   a. Understanding of pre-exposure risk, injury, and biological factors contributing to an individual’s response, recovery, and long-term outcomes following a brain injury or traumatic event. Studies with a biomarker component are allowed. Research of interest includes, but is not limited to:

   - The role of psychological health conditions, genetics, endophenotypes, health demographics, previous injuries or repetitive exposures, pathophysiology, and environmental factors (e.g., extreme temperatures/pressures).

   - Contribution of pre- and post-injury patient, family, and caregiver education, as well as cultural, demographic, stigma, and bias factors that may relate to treatment seeking and adherence.

   - Computational models from clinical data to forecast the long-term and/or late effects of brain exposures, such as TBI, critical traumatic events, and co-occuring conditions.

   b. Approaches for preclinical to clinical translation that expedite and advance prevention and treatment. Studies with a biomarker component are allowed. Research of interest includes, but is not limited to:

   - Pairing clinical populations to animal models in order to validate the clinical relevance and development of prevention and treatment solutions. Animal models should be well-justified, supported within the literature, and clearly align with clinical relevance.

   - Communication, tools/technology adoption, and identification of risk factors, educational barriers, social determinates of health, and other factors that may impede clinical translation.

   c. Understanding the intersection of risk and protective factors in long-term psychological health outcomes. Research of interest includes, but is not limited to:

   - Mental health trajectories associated with trauma and suicidality that incorporate internal and external factors. For example, factors could include time course, demographic characteristics, career course, history of trauma exposure, and community and cultural factors.

   - Understanding the approach to psychiatric diagnosis in the military and the association of psychiatric diagnosis with occupational impairment and military separation.

   d. Understanding sexual harassment and assault prevention, perpetration, victimization, and response. Methodologies that ensure anonymity for participants are encouraged. Research of interest includes, but is not limited to:
• Understanding processes of shame, stigma, and institutional betrayal among sexual assault victims and their units/teams and evaluation of approaches to mitigate these experiences. Experiences of marginalized groups, male victims, and victims of intimate partner violence are of particular interest.

• Understanding how organizational-level factors influence interpersonal and individual conditions, choices, and behaviors as they relate to sexual assault and harassment prevention and response. Measurement and analysis of organizational-level factors, such as culture and climate, beyond aggregating individual perceptions, are encouraged. Research could include the progression from sexual harassment to sexual assault and factors influencing sexual harassment.

• Understanding barriers to reporting sexual assault and factors that contribute to retaliation within units/teams and evaluation of approaches to mitigate barriers and prevent retaliation. Research could include data from influencers, bystanders, and perpetrators; environmental, structural, and demographic factors (e.g., workplace culture, climate, senior leader diversity, age, gender).

2. Prevent: Research will address the prevention or progression of TBI or psychological health conditions through population, selective, and indicated prevention approaches. Efforts that focus on primary prevention (including protection), screening, diagnosis, and prognosis are within scope.

a. Identification and validation of biomarkers or other objective markers for diagnosis, prognosis, or monitoring of psychological health conditions/brain injuries, repetitive exposures, and associated sequelae (e.g., chronic migraine, dizziness, neurocognitive symptoms, sleep, post-traumatic headache). When appropriate, the use of U.S. Food and Drug Administration (FDA)-approved devices is encouraged.

b. Approaches or tools to prevent or mitigate brain injuries or psychological health conditions and assess health status. Research of interest includes, but is not limited to:

• Translation of environmental sensor outputs to conditions within the brain.

• Development of innovative materials and technologies that can prevent or mitigate TBI.

• Generation of physiological evidence regarding the safety, efficacy, and utility of candidate neuroprotective measures. Animal models, if used, should be validated and well-justified within the literature and should demonstrate clear alignment to clinical populations.

• Validated, objective methods for assessing psychological health conditions such as posttraumatic stress disorder (PTSD), adjustment disorders (AdjDs), acute stress reactions (ASRs), major depressive disorder, substance use disorders, suicidality, comorbid conditions, or TBI, and real-time health status monitoring.
• Evidence that existing symptom-based return to activity/duty guidelines protect against risk of persistent symptoms.

• Development of clinical decision-making frameworks or tools that incorporate objective assessments and long-term outcomes to return to activity/duty decisions.

• Development of injury thresholds and exposure standard.

c. Development, evaluation, and implementation of cross-cutting prevention approaches targeting upstream factors or leveraging communities and peers to address multiple adverse outcomes such as suicide, multiple forms of violence, and alcohol and substance misuse. Examples of upstream factors could include social connectedness, inclusiveness, culture, problem-solving, emotional regulation, communication, underlying health disparities, and financial stability. Research of interest may include, but is not limited to:

• Optimized messaging for successful dissemination and implementation.

• Inclusion of families and evaluation of impacts thereon. “Family” should be broadly defined to include not just spouses, but also parents, significant others/fiancées/partners, children, caregivers, or close friends.

d. Solutions to increase readiness and resilience in individuals, small teams, and families to ameliorate the potential negative impacts of specific military and life stressors. Research of interest includes, but is not limited to:

• Effective pharmacologic or non-pharmacologic prevention interventions. Solutions for prevention of ASRs and PTSD may be proposed.

• Preparation of Service Members and units for missions and to help reset between deployments within the Sustainable Readiness Model¹.

• Effective solutions to support relationships and parenting, prepare families for potential secondary trauma exposure, and empower families to access tailored support and resources. “Family” should be broadly defined to include not just spouses, but also parents, significant others/fiancées/partners, children, caregivers, or close friends.

e. Solutions to address aspects of workplace culture and climate (e.g., leadership attitudes, group characteristics, group identification factors) that are associated with increases in harmful behaviors. Research of interest includes, but is not limited to, solutions to provide and incentivize positive options and substitutes for alcohol and substance use and promote pro-social behavioral norms.

3. Treat: Research will address immediate and long-term treatments and improvements in systems of care, including access to and delivery of healthcare services. Treatment topics

¹ https://armypubs.army.mil/epubs/DR_pubs/DR_a/pdf/web/ARN9412_AR525_29_FINAL.pdf
may include novel treatments and interventions, personalized medicine approaches, length and durability of treatment, rehabilitation, relapse, and relapse prevention.

a. Interventions that promote sustained functional recovery, including interventions administered acutely, during the post-acute phase, or during the chronic phase of injury. Research of interest includes, but is not limited to:

- Interventions focused on sensory and locomotor dysfunction after brain injury.
- Interventions that address cognitive functioning and reserve.
- Personalized medicine approaches to treatment that may include tailoring treatment to the biological and endophenotypic elements present. Studies may consider how TBI, PTSD, depression, or other psychological health conditions are interrelated.
- Rapid assessments and treatments for psychological health conditions. Interventions addressing AdjDs, ASRs, and PTSD may be proposed.
- Effective assessments and interventions for delivery in rural or other resource-limited environments (e.g., far-forward military environments), and/or by non-clinicians (e.g., peers, teams, first responders/medics).
- Considerations for sequencing and optimal combinations of pharmacologic and non-pharmacologic interventions.

b. Treatments that promote recovery and improve long-term outcomes. Research of interest includes, but is not limited to:

- Responders versus non-responders to treatment and rehabilitation.
- Novel therapeutic candidates based on evolving changes of pathophysiology and/or theoretical mechanisms of TBI and psychological health.
- Focus on long-term outcomes such as dementia/neurodegeneration, psychological health, family, and well-being are encouraged.
- Interventions emphasizing community-driven participation, inclusion of caregivers/family, and education to facilitate improved functional outcomes are encouraged.

c. Validated individual-, peer-/unit-/team-, leader-, family-, caregiver-, community-, and enterprise-level methods for reducing barriers to care for TBI or multiple mental health challenges (e.g., PTSD, suicidal ideation or behaviors, alcohol and substance use, anxiety, depression) and understanding mechanisms of change in help-seeking behavior.

d. Implementation, follow-up, and services research to increase provider adoption and availability of evidence-based treatments, as well as treatment engagement, follow-up
care, and understanding of long-term outcomes. Research of interest includes, but is not limited to:

- Clinical effectiveness studies comparing new/novel capabilities to existing evidence-based treatments and/or the standard of care.
- Optimized messaging for successful dissemination and implementation of interventions.
- Understanding mechanisms of action for existing evidence-based treatments is also of interest.

e. Effective community-level postvention strategies to address social connectedness during reintegration of individuals into teams following a sexual assault or suicide event. Proposed research should prevent subsequent suicides or other counterproductive behaviors among individuals and community members.

II.B. Award Information

The FY21 TBIPHRP TRA is intended to support translational research that will accelerate the movement of promising ideas in TBI and/or psychological health research into clinical applications, including healthcare products, technologies, and/or clinical practice guidelines. This mechanism supports both preclinical to clinical translational research (e.g., studies of pharmaceuticals and medical devices in preclinical systems) as well as clinical research to clinical care translation (e.g., comparative effectiveness, implementation science, healthcare services research). Observations that support a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan is encouraged to involve a reciprocal flow of ideas and information between basic and clinical science or clinical and implementation science as appropriate. Applications proposing clinical trials for NEW interventions or NEW indications for products currently FDA-approved are not permitted under this funding mechanism and should consider submitting to the following FY21 TBIPHRP funding opportunities:

- Clinical Trial Award (Funding Opportunity Number: W81XWH-21-S-TBIPH1)
- Focused Program Award (Funding Opportunity Number: W81XWH-21-S-TBIPH2)

Applications must include preliminary and/or published data to support the proposed research project. Applications should clearly articulate three points along the translational research spectrum:

- Where the field is now;
- Where the field will be after the successful completion of the proposed research project; and
• What the next step will be after completion of the proposed project.

**Relevance to Military Health:** Relevance to the healthcare needs of Service Members, Veterans, military beneficiaries, and the American public is a key feature of this award. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

- Explanation of how the project addresses an aspect of TBI and/or psychological health that has direct relevance to the health and/or readiness of Service Members, Veterans, military beneficiaries, and the American public
- Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to benefit the civilian population and also address a military need
- Use of military or Veteran populations, samples, or datasets in the proposed research, if appropriate
- Collaboration with DOD or Department of Veterans Affairs (VA) investigators or consultants

Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaborations between researchers at military or Veterans institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique data and research resources that the partners bring to the research effort, ultimately advancing TBI and psychological health research of significance to Service Members, Veterans, military beneficiaries, and the American public. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 2.

**Early-Career Investigator Partnering Option:** The FY21 TBIPHRP encourages applications that include meaningful and productive collaborations between investigators. The FY21 TBIPHRP TRA includes an option with a Principal Investigator (PI) who is an Early-Career Investigator. The PIs may have experience in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The Early-Career Investigator Partnering Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other investigator will be the Partnering PI. **Either the Initiating or Partnering PI may be the Early-Career Investigator.** Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The application is expected to describe how the PIs’ unique experience/expertise combined as a partnership will better address the research question, how the unique experience/expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. If recommended for funding, each PI will be named to an individual award within the recipient organizations. For individual FY21 TBIPHRP
TRA submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DOD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated total costs budgeted for the entire period of performance for an FY21 TBIPHRP TRA will not exceed $1.50M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Awards will be made no later than September 30, 2022. For additional information refer to Section II.F.1, Federal Award Notices.

The CDMRP expects to allot approximately $36M to fund approximately 24 FY21 TBIPHRP Translational Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY21 funding opportunity will be funded with FY21 funds, which will expire for use on September 30, 2027.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Research Protections (ORP), Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 1, and the Human Research Protections Office Resources and Overview document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.
If the proposed research involves more than one institution, plans for the multi-institutional structure governing the research protocol(s) should be outlined.

A written plan for single IRB review arrangements must be provided for cooperative research conducted in the United States. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements. The master protocol and consent form must be reviewed by the HRPO prior to distribution to the additional sites for IRB/EC review. Communication and data transfer between or among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the proposal/application. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials.

**Clinical trials for NEW interventions or NEW indications for products currently FDA-approved are not allowed under this mechanism.** A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Funded trials are required to post a copy of the IRB-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in Code of Federal Regulations, Title 32, Part 219 (32 CFR 219). **This award may not be used to support studies requiring an exception from informed consent (EFIC).**

**Clinical research is defined** as: (1) patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies; (2) epidemiologic and behavioral studies; and (3) outcomes research and health services research. **Note:** Studies that meet the requirements for IRB Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.

**Implementation Research:** Research from this award may support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures to understand, prevent, and treat TBI and psychological health are encouraged.

- For the purposes of the FY21 TBIPHRP TRA, *implementation research* is defined as the scientific study of strategies to adopt and integrate evidence-based health interventions into
clinical and community settings to improve individual outcomes and benefit population health.

**Use of DOD or VA Resources:** If the proposed research involves access to military patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of application submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

Access to certain DOD or VA patient populations, resources, or databases may only be obtained by collaboration with a DOD or VA investigator who has a substantial role in the research and may not be available to a non-DOD or non-VA investigator if the resource is restricted to DOD or VA personnel. Investigators should be aware of which resources are available to them if the proposed research involves a non-DOD or non-VA investigator collaborating with the DOD and/or VA. If the application is recommended for funding, the government reserves the right to withdraw or revoke funding until the PI has demonstrated support for and access to the relevant population(s) and/or resource(s).

**Research Involving Animals:** All DOD-funded research involving new and ongoing research with animals must be reviewed and approved by the USAMRDC ORP Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is not required. Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies. Refer to the General Application Instructions, Appendix 1, for additional information.

**Rigor of Experimental Design:** All projects should adhere to accepted standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Core standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191 (https://www.nature.com/articles/nature11556). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE 2.0 (Animal Research: Reporting In Vivo Experiments) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE 2.0 guidelines can be found at https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000410.

Projects that include research on animal models are required to submit an Animal Research Plan (Attachment 7) as part of the application package to describe how these standards will be addressed, and should likewise follow the ARRIVE 2.0 guidelines referenced above.

**Optimizing Research Impact Through Community Collaboration:** Research funded by the FY21 TBIPHRP should be responsive to the needs of the traumatic brain injury and psychological health lived experience, family, and care provider communities. Through the establishment and utilization of effective and equitable collaborations and partnerships, the translational and impact potential of the proposed research can be maximized. For the FY21
TBIPHRP TRA, inclusion of Community-Based Participatory Research (CBPR) approaches is encouraged, particularly for studies involving human subjects, but not required.

CBPR supports collaborative research that involves scientific researchers and community members working together to address diseases and conditions, particularly those that disproportionately affect health disparity populations. Recognizing the strength of each partner, scientific researchers and community members collaborate and contribute equitably their expertise on all aspects of the project, which may include a needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. CBPR features shared responsibility and ownership for the research project, and research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. CBPR methods are critically important for community-level interventions and for conditions affecting health disparity populations; CBPR methods, such as Lived Experience Consultation (LEC), can also have important impacts on translational research and prototype development to identify and augment the potential impact of a research program on people living with TBI and/or psychological health conditions.

CBPR is characterized by the equitable collaboration between community members and researcher. These collaborative relationships are often established through integrating community members into research teams as co-researchers, advisors, and consultants. Some examples for CBPR collaborations include:

- **LEC**: The research team includes at least one project advisor with lived TBI and/or psychological health experience who will provide advice and consultation throughout the planning and implementation of the research project. Lived experience consultants may include individuals with a TBI or psychological health condition, their family members, or care partners.

- **Partnership with a community-based organization**: The research team establishes partnerships with at least one community-based organization that provides advice and consultation throughout planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policy makers, or other formal organizational stakeholders.

- **Community advisory board (CAB)**: A CAB is composed of multiple community stakeholders and can take many forms, from a board of lived experience consultants to a coalition of community-based organizations or any combination thereof. As with LEC and organizational partners, the CAB provides advice and consultation throughout planning and implementation of the research project.

Additional information on CBPR can be found here:


Required Data Sharing for Traumatic Brain Injury and Psychological Health Human Subjects Research: The CDMRP intends that information, data, and research resources generated under this funding opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.

For traumatic brain injury and psychological health research, the National Research Action Plan recommends the use of common data elements (CDEs) to facilitate sharing of data to promote collaboration, accelerate research, and advance knowledge on characterization, prevention, diagnosis, and treatment of traumatic brain injury and psychological health conditions.

• All Prospective Human Subject Research
  o Applicants must include language in informed consent documents to allow for submission of de-identified data to a repository or for secondary use/meta-analyses of the data.
  o Applicants are also strongly encouraged to include language in consent forms to allow for optional passive follow-up via electronic health record.
  o As applicable, applicants are strongly encouraged to include secondary outcomes in proposed studies to address potential cross-cutting impacts of interventions.
  o As appropriate, the inclusion of both TBI and psychological health measures is strongly encouraged, regardless of the primary focus of the study.

• Psychological Health Research
  o The TBIPHRP requires applicants to incorporate CDEs appropriate to each field of study, such as the PhenX Core and Specialty collections, which are available in the Mental Health Research, Substance Abuse and Addiction, and Research Domains Collections of the PhenX Toolkit, into all studies involving human subjects as applicable. Justification is required if the recommended measure in the PhenX Toolkit is not selected.

• Traumatic Brain Injury Research
  o The TBIPHRP requires that awardees make TBI research data generated by this award mechanism available to the research community through the Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System. The FITBIR Informatics System is a free resource designed to accelerate research progress by allowing the storage, re-analysis, integration, and rigorous comparison of multiple datasets. Currently, FITBIR-eligible research includes all studies generating prospectively collected human TBI subject data (e.g., clinical, demographic, phenotypic, imaging, genetic).
In order to share data with FITBIR, these elements must be included in the proposed research:

- Updated informed consent language that includes FITBIR data sharing. Sample consent language is included in Appendix 3.

- Global Unique Identifier (GUID): FITBIR encourages collaboration between laboratories, as well as interconnectivity with other informatics platforms. Such community-wide sharing requires common data definitions and standards. FITBIR allows for de-identification and storage of data (medical imaging clinical assessment, environmental and behavioral history, etc.) of various types (text, numeric, image, time series, etc.). Use of FITBIR’s GUID system facilitates repeated and multi-user access to data without the need to personally identify data sources. In order to generate a GUID for a subject, the following personally identifiable information (PII) must be collected in the proposed research:
  
  - Complete legal given (first) name of subject at birth
  - Complete legal additional name of subject at birth (if subject has a middle name)
  - Complete legal family (last) name of subject at birth
  - Day of birth
  - Month of birth
  - Year of birth
  - Name of city/municipality in which subject was born
  - Country of birth

  Note that this PII is never sent to the FITBIR system. PII cannot be extracted from the GUID. Information on GUID compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations can be found on the National Institutes of Health (NIH) website: https://fitbir.nih.gov/content/global-unique-identifier.

- NINDS TBI CDEs: Research data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI CDEs or entered into the FITBIR data dictionary as new, unique data elements (UDEs). For the most current version of the NINDS TBI CDEs, go to http://www.commondataelements.ninds.nih.gov. Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs collected are compatible with the FITBIR Informatics System. Use of the TBI CDEs is required as applicable in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical studies of TBI. Applicants are strongly required to review TBI CDEs and associated form structures during the development of the study.
collection methods. *If approved CDEs are not incorporated, justification is required and subject to program approval.*

- While there is no direct charge to users of the FITBIR Informatics System, a project estimation tool ([https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp](https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp)) is available to help estimate costs and manpower needs that may be associated with data submission.

- FITBIR guidance and policies, as well as the considerable advantages of FITBIR participation to the researcher, are detailed at [http://fitbir.nih.gov/](http://fitbir.nih.gov/).

**Conducting DOD-Funded Human Research with Military Populations:** There are unique requirements and prohibitions for compensating DOD-affiliated personnel for study participation and for conducting research with military families/children and U.S. Army Special Operations Command populations. Additional information regarding conducting DOD-funded human research with military populations can be found at [https://cdmrp.army.mil/pubs/pdf/Conducting%20Research%20Military%20Pop%20DOD_June%202021.pdf](https://cdmrp.army.mil/pubs/pdf/Conducting%20Research%20Military%20Pop%20DOD_June%202021.pdf).

**II.C. Eligibility Information**

**II.C.1. Eligible Applicants**

**II.C.1.a. Organization:** All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

**Government Agencies Within the United States:** Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

- **Extramural Organization:** An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organization other than the DOD, and research institutes.

- **Intramural DOD Organization:** A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center.* Intramural Submission: Application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.*

**USAMRAA makes awards to eligible organizations, not to individuals.**

**II.C.1.b. Principal Investigator(s)**

Independent investigators at all academic levels (or equivalent) may be named by the organization as the PI on the application.
II.C.1.c. Early-Career Investigator Partnering Option

The Early-Career Investigator must be an independent investigator within 10 years after completion of their terminal degree by the time of the application submission deadline (excluding time spent in residency or on family medical leave). Time spent as a postdoctoral fellow is not excluded. Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at https://orcid.org/.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access .gov and .mil websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to Section II.H.2, Administrative Actions, for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

Extramural Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DOD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.
II.D.1. Address to Request Application Package

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance.

Contact information for the CDMRP Help Desk and the Grants.gov Contact Center can be found in Section II.G, Federal Awarding Agency Contacts.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both pre-application (eBRAP.org) and full application (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to Table 1, Full Application Guidelines).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

Early-Career Investigator Partnering Option: The Initiating PI must complete the pre-application submission process and submit the contact information for the Partnering PI. The Partnering PI will then be notified of the pre-application submission separately by email. The Partnering PI must follow the link in the notification email in order to associate their full application package with that of the Initiating PI. After following the link, the Partnering PI must verify their contact information, organization, and designation as an extramural or intramural submission within eBRAP. If not previously registered, the Partnering PI must register in eBRAP. A new pre-application based on this research project should not be initiated by the Partnering PI. Applicants are urged to complete these steps as soon as possible. If they are not completed, the Partnering PI will not be able to view and modify their application during the verification period in eBRAP. If these steps are not completed, an intramural partner will not be able to submit the Partnering PI’s required full application package components to eBRAP.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.
To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. **Incorrect selection of extramural or intramural submission type will delay processing.**

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the Initiating PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The applicant organization and associated PIs identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

A change in PI or organization after submission of the pre-application may be allowed after review of a submitted written appeal (contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507) and at the discretion of the USAMRAA Grants Officer.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

  Submission of application information includes assignment of primary and secondary research classification codes, which may be found at https://ebrap.org/eBRAP/public/Program.htm. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

  When starting the pre-application, applicants will be asked to select a “Mechanism Option”. Applicants are responsible for selecting the appropriate option for the pre-application:

<table>
<thead>
<tr>
<th>Application Includes</th>
<th>Select Option</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single PI</td>
<td>No Option</td>
</tr>
<tr>
<td>Initiating PI and Early-Career Investigator</td>
<td>Early-Career Investigator Partnering</td>
</tr>
<tr>
<td>Early-Career Initiating PI and Partnering PI</td>
<td>Early-Career Investigator Partnering</td>
</tr>
</tbody>
</table>

- **Tab 2 – Application Contacts**

  Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this
application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application.

**FY21 TBIPHRP Programmatic Panel members** should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to Section II.H.2.c, Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

**Early-Career Investigator Partnering Option:** The Initiating PI must enter the contact information for the Partnering PI in the Partnering PI section.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

*Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.*

- **Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Focus Area:** Describe how the project addresses an important question in at least one *sub-area within one of the three FY21 TBIPHRP TRA Focus Areas.*
- **Rationale:** State the hypothesis and reasoning on which the proposed research project is based. Briefly describe how preliminary data, scientific rationale, and referenced literature support the research hypothesis. Clearly demonstrate that there is sufficient rationale for the project.

- **Specific Aims and Study Design:** Clearly describe the type of research study being proposed. Concisely state the project’s objectives, specific aims, and ultimate endpoints. If applicable, describe the animal models to be used and their relevance to human disease. If clinical research/trial is proposed, briefly describe the proposed recruitment strategies and methods, how they will accomplish the project’s aims, as well as the outcomes measures that will be used. Describe how the outcome of the clinical research/trial will advance the field and inform the next step in the continuum of translational research.

- **Research Team:** Provide a description of the PI(s) and key personnel that clearly demonstrates the appropriate background and experience to accomplish the proposed work.

- **Impact and Relevance to Military Health:** Describe the potential near-term and long-term impact of the proposed research on a critical problem or question in the field of TBI and/or psychological health research and/or patient care. Explain how the effort is relevant to the healthcare needs of Service Members, Veterans, and/or military beneficiaries.

- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application must be uploaded as individual files and are limited to the following:
  - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
  - **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.
  - **Key Personnel Biographical Sketches (six-page limit per individual):** All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- **Tab 6 – Submit Pre-Application**

  This tab must be completed for the pre-application to be accepted and processed.
Pre-Application Screening

- **Pre-Application Screening Criteria**

  To determine the technical merits of the pre-application and the relevance to the mission of the Defense Health Program (DHP) and the TBIPHRP, pre-applications will be screened based on the following criteria:

  - **Focus Area:** How well the proposed study addresses an important question in at least one sub-area within one of the three FY21 TBIPHRP TRA Focus Areas.

  - **Rationale:** How well the hypothesis is stated and supported through preliminary data, scientific rationale, and referenced literature.

  - **Specific Aims and Study Design:** To what degree the objectives and specific aims support the research idea. If animal models are described, how relevant the animal model is to human disease. If clinical research/trial is proposed, how well the described proposed recruitment strategies, methods, and outcomes measures will accomplish the project’s aims. To what degree the outcome of the clinical research/trial will advance the field and inform the next step in the continuum of translational research.

  - **Research Team:** Whether the background and experience of the PI(s) and key personnel are appropriate to perform the proposed research.

  - **Impact and Relevance to Military Health:** Whether the proposed research will have a potential near-term and long-term impact on a critical problem or question in the field of TBI and/or psychological health research and/or patient care. To what degree the project is relevant to the healthcare needs of Service Members, Veterans, and/or military beneficiaries.

- **Notification of Pre-Application Screening Results**

  Following the pre-application screening, Initiating PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in Section I, Overview of the Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

**II.D.2.b. Step 2: Full Application Submission Content**

Applications will not be accepted unless notification of invitation has been received by the PI or Initiating PI.

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*
Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (https://www.grants.gov/) for extramural organizations or through eBRAP (https://ebrap.org/) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader must be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the same version of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (https://www.grants.gov/web/grants/applicants/apply-for-grants.html) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

Do not password protect any files of the application package, including the Project Narrative.

Table 1. Full Application Submission Guidelines

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DOD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Application Package Location</strong></td>
<td><strong>Application Package Location</strong></td>
</tr>
<tr>
<td>Download application package components for W81XWH-21-TBIPHRP-TRA from Grants.gov (<a href="https://www.grants.gov">https://www.grants.gov</a>) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.</td>
<td>Download application package components for W81XWH-21-TBIPHRP-TRA from eBRAP (<a href="https://ebrap.org">https://ebrap.org</a>).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Full Application Package Components</th>
<th>Full Application Package Components</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SF424 Research &amp; Related Application for Federal Assistance Form:</strong> Refer to the General Application Instructions, Section III.A.1, for detailed information.</td>
<td><strong>Tab 1 – Summary:</strong> Provide a summary of the application information. <strong>Tab 2 – Application Contacts:</strong> This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</td>
</tr>
</tbody>
</table>
## Extramural Submissions

Descriptions of each required file can be found under Full Application Submission Components:

- Attachments
- Research & Related Personal Data
- Research & Related Senior/Key Person Profile (Expanded)
- Research & Related Budget
- Project/Performance Site Location(s) Form
- Research & Related Subaward Budget Attachment(s) Form

## Intramural DOD Submissions

Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:

- Attachments
- Key Personnel
- Budget
- Performance Sites

Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.

## Application Package Submission

**Create a Grants.gov Workspace.**

Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.

**Submit a Grants.gov Workspace Package.**

An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package **at least 24-48 hours prior to the close date** to allow time to correct any potential technical issues that may disrupt the application submission.

**Note:** If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or the budget needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID **prior to** the application submission deadline. **Do not password protect any files of the application package, including the Project Narrative.**

**Submit package components to eBRAP** ([https://ebrap.org](https://ebrap.org)).

**Tab 5 – Submit/Request Approval Full Application:** After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official by email. **Do not password protect any files of the application package, including the Project Narrative.**
### Application Verification Period

<table>
<thead>
<tr>
<th>Extramural Submissions</th>
<th>Intramural DOD Submissions</th>
</tr>
</thead>
<tbody>
<tr>
<td>The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified with the exception of the Project Narrative and Research &amp; Related Budget Form.</td>
<td>After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI(s) will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified with the exception of the Project Narrative and Research &amp; Related Budget Form. Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.</td>
</tr>
</tbody>
</table>

### Further Information

**Tracking a Grants.gov Workspace Package.**
After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.</td>
<td></td>
</tr>
</tbody>
</table>

**Early-Career Investigator Partnering Option:** The CDMRP requires separate full application package submissions for the Initiating PI and the Partnering PI, even if the PIs are located within the same organization. Initiating and Partnering PI will each be assigned a unique eBRAP log number. Each full application package must be submitted using the unique eBRAP log number. **Note:** All associated applications (Initiating PI’s and the Partnering PI’s) must be submitted by the full application submission deadline.

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

**II.D.2.b.ii. Full Application Submission Components**

- **Extramural Applications Only**

  **SF424 Research & Related Application for Federal Assistance Form:** Refer to the General Application Instructions, Section III.A.1, for detailed information.
Extramural and Intramural Applications

Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB, and the file size for the entire full application package may not exceed 200 MB.

○ Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”. The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

- **Background:** State the relevance of the proposed research and applicability of the anticipated findings to adhere to the intent of the mechanism and at least one sub-area within one of the three FY21 TBIPHRP TRA Focus Areas. Describe in detail the scientific rationale for the study and include a literature review, unpublished data, preliminary studies, and/or preclinical data that support the development of the proposed project. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or hypotheses. Provide a summary of relevant prior preclinical and/or clinical work and distinguish how the proposed study differs from other relevant or recently completed research. If applicable, describe any stakeholder engagement that was performed and how it helped to formulate the hypothesis/objective and research strategy. For implementation studies, include a discussion of any current clinical use of the interventions under investigation and/or details of its study in clinical research for other indications, if applicable.

- **Objectives/Specific Aims/Hypothesis:** Provide a description of the purpose and objectives of the study with detailed specific aims and hypotheses. The aims should align with the primary aims and associated tasks described in the SOW (Attachment 5). If the proposed research project is part of a larger study, present only tasks that this FY21 TBIPHRP TRA would fund.
Research Strategy:

- Identify and describe how the study design, methods, models, and analyses will meet the project’s goals and milestones.
- Describe how the proposed project is feasible and will be completed within the proposed performance period.
- Address potential problem areas and pitfalls, and provide alternative methods and approaches.
- If animals are to be used, justify why the proposed animal model(s) were chosen and discuss the model’s relevance to human disease. Additional detailed information regarding animal model relevance and experimental procedures will be required in the Animal Research Plan (Attachment 7).
- For studies performing prospective human subject recruitment or observation, describe the population(s) of interest and how access to the population(s) will be achieved; full details will be required in the Clinical Strategy Statement (Attachment 8).

Statistical Plan and Data Analysis: Describe the statistical model and data analysis plan with respect to the study objectives. If applicable, specify the approximate number of human subjects to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study and all proposed correlative studies. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study. For phase 3 clinical trials, describe plans for the valid analysis of group differences on the basis of sex/gender, race, and/or ethnicity as appropriate for the scientific goals of the study. Ensure sufficient information is provided to allow thorough evaluation of all statistical calculations during review of the proposal/application.

Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”. Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e.,
author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

- **Letters of Organizational Support (three-page limit per letter):** Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

- **Letters of Collaboration, if applicable (two-page limit per letter):** Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.

- **CBPR Letters of Commitment, if applicable (two-page limit per letter):** Provide a letter signed by each lived experience consultant or community-based partner(s) confirming their role and commitment to participate on the research team. The letter should include the qualifications and background of the lived experience consultant(s) or community-based partner(s) and their relevance to the proposed research project.

- **CBPR Statement, if applicable (three-page limit):** Describe the CBPR approach that will be used (e.g., LEC, partner organization, CAB, co-researcher model) and at what points CBPR will be employed in the study. The statement should also include:

  - Description of the CBPR approach that will be used (e.g., LEC, partner organization, CAB, co-researcher model) and at what points in the research project.
- Description of the input that will be captured and how this input will be meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and dissemination of the research.

- Description of training that will be provided to both scientific researchers and community members on CBPR approaches, decision-making, and equitable participation.

- Description of co-learning and capacity-building activities among all partners.

- Description of resource allocation, decision-making processes, and authorship between scientific researchers and community partners (whether individuals or organizations).

- Description of process measures to assess the effectiveness of the chosen CBPR approach.

- Description of dissemination activities with particular focus on feeding back the data to affected communities.

- **Intellectual Property:** Information can be found in 2 CFR 200.315, “Intangible Property.”

  - **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community, including the sharing of de-identified data with data repositories.

  For applications involving FITBIR-eligible TBI research:

  - Identify and describe the planned NINDS TBI CDEs, alignment to FITBIR data elements and forms, and timelines for integrating data to the FITBIR Informatics System.

  - For UDEs, provide a justification as to why existing CDEs are not applicable or appropriate.

  For applications involving psychological health research:

  - Identify and describe the planned CDEs appropriate to each field of study, such as the PhenX Core and Specialty collections.

  - Provide justification if the recommended measure in the PhenX Toolkit is not selected.
In preparing requested budgets, applicants may include anticipated costs associated with data and research resource sharing (i.e., making a large dataset available to the public or developing an important resource for the scientific community).

Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.

- **Use of DOD Resources (if applicable):** Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to military populations and/or DOD resources or databases.

- **Use of VA Resources (if applicable):** If the proposed research involves access to VA patient populations, VA study resources and databases, and/or VA research space and equipment, VA PIs must have a plan for obtaining and maintaining access throughout the proposed research. Access to VA patients, resources, and/or VA research space should be confirmed by including a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief. If appropriate, the application should identify the VA-affiliated non-profit corporation (NPC) as the applicant institution for VA PIs. If the VA NPC is not identified as the applicant institution for administering the funds, the application should include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf”. The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. **Do not include proprietary or confidential information.** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

  Technical abstracts should be written using the outline below. The technical abstract should provide an appropriate description of the project’s key aspects; clarity and completeness within the space limits of the technical abstract are highly important.

  - **Background:** State how the proposed research addresses one or more sub-area within one of the three FY21 TBIPHRP TRA Focus Areas. Present the ideas and reasoning behind the proposed work.

  - **Objective/Hypothesis:** State the objective to be reached or the hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.

  - **Specific Aims:** State the specific aims of the study.

  - **Study Design:** Briefly describe the study design.
− **Impact:** Briefly describe the potential near-term and long-term impact of the results of the proposed research on TBI and/or psychological health.

− **Relevance to Military Health:** Explain how the project is relevant to the healthcare needs of Service Members, Veterans, and/or military beneficiaries.

○ **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”**. The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information. Do not duplicate the technical abstract.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Minimize use of acronyms and abbreviations, where appropriate. The lay abstract is an important component of the application review process because it addresses issues of particular interest to lived experience subject matter experts (consumers).

− Describe the objectives and rationale for the proposed project in a manner that can be *readily understood by readers without a background in science or medicine.*

− Describe the ultimate applicability of the research and how it addresses at least one *sub-area within one of the three FY21 TBIPHRP TRA Focus Areas.*

− Describe the types of patients that will be helped by the research and how it will help them.

− Describe potential clinical applications, benefits, and risks.

− Describe the projected timeline to achieve the expected patient-related outcome.

− Describe how the proposed project will impact the health and well-being of Service Members, Veterans, and/or military beneficiaries.

○ **Attachment 5: Statement of Work (five-page limit): Upload as “SOW.pdf”**. The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)). Recommended strategies for assembling the SOW can be found at [https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm).

For the FY21 TBIPHRP TRA, refer to either the “*Suggested SOW Strategy Clinical Research*” or “*Suggested SOW Strategy Generic Research*”, whichever format is most appropriate for the proposed effort, and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within
the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also include:

- If applicable, cross mapping of data elements to TBI and/or psychological health CDEs.

- For FITBIR eligible research include:
  - FITBIR investigator and study registration within the first 30 days of the award
  - Sharing of draft data collection forms with FITBIR
  - Annual FITBIR data submissions

**Early-Career Investigator Partnering Option:** Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and the Partnering PI should be noted for each task.

- Attachment 6: Impact and Relevance to Military Health Statement (five-page limit): Upload as “Impact.pdf”. This attachment should be written in a manner that will be *readily understood by readers without a background in science or medicine.*

  - **Describe the near-term impact:** Detail the anticipated outcome(s) or knowledge/materiel product(s) that will make important scientific advances and improve the understanding, prevention, and/or treatment of TBI and/or psychological health conditions.

  - **Describe the long-term impact:** Explain the long-range vision for how the research will impact the field of study and/or the lives of relevant patient or community populations. Explain the anticipated long-term benefits from this research in the clinic or field. Discuss how the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, non-pharmacological approaches, devices, or clinical practice guidance, if applicable.

  - For implementation studies, describe how the research will contribute to the implementation of evidence-based interventions, tools, policies, and guidelines (as applicable).

  - Describe how the proposed effort is responsive to the healthcare needs of Service Members, Veterans, and/or military beneficiaries.

    - If applicable, clearly articulate how the proposed research will be able to enhance readiness and recovery on the battlefield, during training, or in resource-limited environments.

    - If applicable, describe how the study team composition is able to provide military-relevant subject matter expertise to the proposed research.
If applicable, show how the proposed research project aligns with DOD and/or VA areas of research interest and/or patient care for TBI and/or psychological health. Provide a description of how the knowledge, information, products, or technologies gained from the research could be implemented in a dual-use capacity to benefit the civilian population and address a military need, as appropriate.

- Describe potential issues that might limit the impact of the proposed research and strategies that may be employed to overcome those issues.

○ **Attachment 7: Animal Research Plan (if applicable; required for all studies utilizing animals; five-page limit per animal study): Upload as “AnimRschPln.pdf”.** When the proposed study involves animals, the applicant is required to submit a plan describing the animal research that will be conducted. Applicants should not submit a verbatim replica of the protocol(s) to be submitted to the IACUC as the Animal Research Plan. The Animal Research Plan should address the following points for each proposed animal study:

  - Briefly describe the research objective(s) of the animal study. Provide evidence that the chosen animal model(s) is validated and well-justified in the literature. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and the relevance to human biology.

  - Describe approaches that will be undertaken to validate or corroborate findings from animal studies to relevant human data sources/populations. This could include, but is not limited to, validation of animal transcriptomic data using publicly available human transcriptomic datasets, confirmation of histological findings in a human post mortem case series, and validation against fluid-based or imaging biomarkers.

  - Describe how the proposed validation approaches or corroborative studies “de-risk” the possibility that the findings from the animal study cannot be translated into human populations.

  - Summarize the procedures to be conducted. Describe how the study will be controlled.

  - Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.

  - Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).

  - Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA or next stage of development, if applicable.
Attachment 8: Clinical Strategy Statement (no page limit): Upload as “Clinical.pdf”. (Attachment 8 is only applicable and required for applications that are recruiting human subjects.) Applications proposing clinical trials for NEW interventions or NEW indications for products currently FDA-approved are not permitted under this funding mechanism.

- Describe the scientific rationale for the proposed clinical research/trial and the endpoints to be measured.

- For studies evaluating established intervention(s), provide a description of the intervention(s) and a brief summary of the relevant clinical setting(s) where the intervention was shown to be efficacious and significantly mature.

- Study Population: Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, and pertinent demographic characteristics of the accessible population at the study site(s) (population from whom the sample will be recruited/drawn). Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual and retention goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical research/trial(s), if applicable. Identify any potential barriers to accrual/retention and provide mitigation plans for addressing unanticipated delays (e.g., slow accrual, attrition). Identify ongoing clinical trials that may compete for the same patient population and how they may impact enrollment progress. Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender. For clinical research/trial(s) proposing to include military personnel, refer to the General Application Instructions, Appendix 1, for more information.

- Inclusion/Exclusion Criteria: List the inclusion and exclusion criteria for the proposed clinical research/trial. Describe how the inclusion and exclusion criteria meet the needs of the proposed clinical research/trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

- Women and Minorities in the Study: Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical research/trial appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The suggested Inclusion
Enrollment Report format is a one-page fillable PDF form, which can be downloaded from eBRAP at https://ebrap.org/eBRAP/public/Program.htm.

- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).
  
  ▪ Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
  
  ▪ If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.
  
  ▪ Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.

- **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects (including vulnerable populations). *This award may not be used to support studies requiring EFIC.*
  
  ▪ *For the proposed study, provide a draft, in English, of the Informed Consent Form. FITBIR-eligible applications should include FITBIR consent language (see Appendix 3 for sample consent language).*

    ▪ Applicants must include language in informed consent documents to allow for submission of de-identified data to a repository or for secondary use/meta-analyses of the data. Provide justification if this is not possible.

    ▪ Applicants are also strongly encouraged to include language in consent forms to allow for optional passive follow-up via electronic health record.

  
  ▪ Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the trial.

  ▪ Include information regarding the timing and location of the consent process.

  ▪ Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.

  ▪ Address how privacy and time for decision-making will be provided and whether the potential human subject will be allowed to discuss the study with anyone before making a decision.
Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.

Describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. **Note:** In compliance with 10 USC 980 (https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf), the application must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical research/trial. If applicable, refer to the General Application Instructions, Appendix 1, for more information.

**Assent:** If minors or other populations that cannot provide informed consent are included in the proposed clinical research/trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.

- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. **Note:** Some screening procedures may require a separate consent or a two-stage consent process.

- **Risks/Benefits Assessment:**
  - **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical research/trial. Consider psychological, legal, social, and economic risks as well as physical risks. Consider how the proposed clinical research/trial might affect the daily lives of the individual human subjects participating in the study. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.
  - **Risk management and emergency response:**
    - Appropriate to the study’s level of risk, describe how safety monitoring and reporting to the IRB and FDA (if applicable) will be managed and conducted.
    - Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.

Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).

Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.

Potential benefits: Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research. Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.

Attachment 9: Data Management (no page limit): Upload as “Data_Manage.pdf”. (Attachment 9 is only applicable and required for applications that propose recruitment of human subjects.)

The Data Management attachment should include the components listed below.

- Data Management: Describe all methods used for data collection, including the following:
  - Identifiers: Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
  - Confidentiality:
    - Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
    - Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DOD are eligible to review study records.
    - Address requirements for reporting sensitive information to state or local authorities.
  - Data capture, verification, and disposition: Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the
database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.

- **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA, if applicable.

- **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

- **Laboratory Evaluations:**

  - **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated and relevance to the study objectives described. The collection schedule and amount of material collected must also be clearly described.

  - **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations are relevant to the study objectives (or to monitor safety of human subjects).

  - **Storage:** Describe specimen storage, including location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use, including considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

  - **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, the applicable quality standard, and any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

- **Attachment 10:** *Questionnaires and Other Research Data Collection Instruments, if applicable (no page limit): Upload as “Data_Collection.pdf”. (Attachment 10 is only applicable and required for applications that propose recruitment of human subjects.)*

The Questionnaires and Other Research Data Collection Instruments attachment should include a copy of the most recent version of data collection forms, rating scales, interview guides, or other instruments. For each instrument:
Describe how the information collected is related to the objectives of the study.

Describe an implementation plan for how and when the instrument(s) will be administered.

Describe how the instrument(s) will be adapted to the subject population(s), if applicable. If the adaptation results in a deviation from validated instruments, please justify.

Attachment 11: Transition Plan (three-page limit): Upload as “Transition.pdf”. Provide information on the methods and strategies proposed to move the product or knowledge outcomes of the program to the next phases of development and/or clinical use following the successful completion of the proposed effort. Articulate this information for the overall effort as well as the individual projects. Applicants are encouraged to work with their organization’s Technology Transfer Office (or equivalent) to develop the transition plan. The post-award transition plan should include the components listed below, as appropriate.

- A description of the outcomes expected upon completion of the proposed research efforts. Outcomes should be relevant, measurable, and include the intended end-user.

- Details of the funding strategy that will be used to bring the outcomes to the next phase of development and/or delivery to market or incorporation into patient care (e.g., specific potential industry partners, specific funding opportunities to be applied).

- A description of collaborations and other resources that will be used to provide continuity of development.

  - For knowledge products\(^2\), include proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications.

- A brief schedule and milestones for bringing the outcomes to the next phase of development (e.g., further research, clinical trials, transition to industry, delivery to the market, incorporation into clinical practice, approval by the FDA).

- If applicable, ownership rights and/or access to the appropriate intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government’s ability to access such products or technologies in the future.

\(^2\) A “knowledge product” is a non-materiel product that addresses an identified need, topic area, or capability gap; is based on current evidence and research; aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities]; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
– A risk analysis for cost, schedule, manufacturability, and sustainability.

○ Attachment 12: Partnership Statement (one-page limit): Upload as “Partnership.pdf”. (Attachment 12 is only applicable and required for applications submitted under the Early-Career Investigator Partnering Option.)

– Provide a statement confirming that the Early-Career Investigator meets the eligibility requirements.

  ▪ Provide the completion dates of the terminal degree and last postdoctoral/fellowship position.

  ▪ Provide an explanation of any lapses in research time or appointments as denoted in the biographical sketch.

– Describe how the partnership and combined experience/expertise of both PIs are critical to the research strategy and completion of the SOW.

– Explain how the partnership will better address the research question and why the work should be done together rather than through separate individual efforts.

– Explain how both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project.

– Explain how funding will be balanced between both PIs, unless otherwise warranted and clearly justified.

○ Attachment 13: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.

○ Attachment 14: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”. If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.
• **Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681[a] et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

**Research & Related Personal Data:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

  ○ **PI Biographical Sketch (six-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page ([https://ebrap.org/eBRAP/public/Program.htm](https://ebrap.org/eBRAP/public/Program.htm)) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

  ○ **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
    – For extramural submissions, refer to the General Application Instructions, Section III.A.4 for detailed information.
    – For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.

  ○ **Key Personnel Biographical Sketches (six-page limit each):** Upload as “Biosketch_LastName.pdf”.

  ○ **Key Personnel Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.

**Research & Related Budget:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

**Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.
Early-Career Investigator Partnering Option: Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI even if they are located within the same organization. Refer to Section II.D.5, Funding Restrictions, for detailed information.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

- Extramural Applications Only

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

  - Extramural Subaward: Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

  - Intramural DOD Collaborator(s): Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as Attachment 14. (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

Suggested DOD Military Budget Format: A military facility collaborating in the performance of the project (but not participating as a Partnering PI) should be treated as a subaward for budget purposes. Note: Applicants should complete a separate military budget using “Suggested Collaborating DOD Military Facility Budget Format” (available for download on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm]) (Attachment 14) to show all direct and indirect costs. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

Application Components for the Partnering PI if applying under the Early-Career Investigator Partnering Option

The Partnering PI must follow the link in the email from eBRAP and, if not registered in eBRAP, complete the registration process prior to the application submission deadline in order to associate their full application package with that of the Initiating PI.
For the Partnering PI, the Initiating PI must identify if the Partnering PI will be named on an extramural or intramural application (in accordance with the guidelines in Section II.C.1.a, Organization) and the appropriate mode of submission (Grants.gov for extramural and eBRAP for intramural). The Partnering PI must verify their contact information and mode of submission within eBRAP to ensure proper submission of their application.

The application submission process for the Partnering PI uses an abbreviated full application package that includes:

- **Extramural and Intramural Applications**

  **Attachments:**
  - **Attachment 5: Statement of Work (five-page limit):** Upload as “SOW.pdf”. Refer to the General Application Instructions, Section III.A.2, for detailed information on completing the SOW. Each PI must submit an identical copy of a jointly created SOW. The contributions of the Initiating PI and the Partnering PI should be noted for each task.
  - **Attachment 13: Representations:** Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations template available on eBRAP (https://ebrap.org/eBRAP/public/Program.htm). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.
  - **Attachment 14: Suggested Collaborating DOD Military Facility Budget Format:** Upload as “MFBudget.pdf”. Refer to the General Application Instructions, Section IV.A.4, for detailed information. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs.

**Research & Related Personal Data:** Refer to the General Application Instructions, Section III.A.3, for detailed information.

**Research & Related Senior/Key Person Profile (Expanded):** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4 for detailed information.

  - **PI Biographical Sketch (six-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in the PDF format that is not editable.
  - **PI Previous/Current/Pending Support (no page limit):** Upload as “Support_LastName.pdf”.
  - **Key Personnel Biographical Sketches (six-page limit each):** Upload as “Biosketch_LastName.pdf”.
○ Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

**Research & Related Budget:** For extramural submissions, refer to the General Application Instructions, Section III.A.5, for detailed information.

**Budget Justification (no page limit):** Upload as “BudgetJustification.pdf”.

**Early-Career Investigator Partnering Option:** Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI even if they are located within the same organization. Refer to Section II.D.5, Funding Restrictions, for detailed information.

**Project/Performance Site Location(s) Form:** For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to General Application Instructions, Section IV.A.5, for detailed information.

- **Extramural Applications Only**

**Research & Related Subaward Budget Attachment(s) Form:**

○ **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.)

○ **Intramural DOD Collaborator(s):** Complete a separate DOD military budget, using Suggested Collaborating DOD Military Facility Budget Format (available for download on the eBRAP “Funding Opportunities & Forms” web page [https://ebrap.org/eBRAP/public/Program.htm]), and upload to Grants.gov attachment form as Attachment 14. (Refer to the General Application Instructions, Section III.A.8, for detailed information.)

**II.D.3. Dun and Bradstreet Data Universal Numbering System (DUNS) Number and System for Award Management (SAM)**

Applicant organizations and all sub-recipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Verify the status of the applicant organization’s Entity registration in SAM well in advance of the application submission deadline. Allow several weeks to complete the entire SAM registration process. If an applicant has not fully complied with the requirements at the time the federal awarded agency is ready to make a federal award, the federal awarding agency may determine that the applicant is not qualified to receive a federal award and use that determination as a basis for making a federal award to another applicant. Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.
Announcement of Transition to SAM-Generated Unique Entity Identifier (UEI): Through April 2022, a transition from DUNS to the SAM-generated UEI will occur. Refer to the General Application Instructions, Section III.1, DUNS Number, for more information on the transition and timing.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in Section I, Overview of the Funding Opportunity. Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI(s) will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, with the exception of the Project Narrative and Budget Form, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.
For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

Single PI Option:

The maximum period of performance is 4 years.

The anticipated total costs budgeted for the entire period of performance will not exceed $1.50M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the government exceeding $1.50M total costs or using an indirect cost rate exceeding the organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

Early-Career Investigator Partnering Option:

The maximum period of performance is 4 years.

The anticipated total costs budgeted for the entire period of performance will not exceed $1.50M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate. The combined budgeted total costs approved by the government will not exceed $1.50M or use an indirect cost rate exceeding each organization’s negotiated rate.

A separate award will be made to each PI’s organization.

The PIs are expected to be partners in the research, and total cost funding should be divided accordingly, unless otherwise warranted and appropriately justified.

The applicants may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years. The duration of the period of performance for the Initiating PI and Partnering PI should be the same.

For this award mechanism, direct costs must be requested for (not all-inclusive):

- Travel costs for the PI to present project information or disseminate project results at a DOD-sponsored meeting (e.g., progress review meeting or Military Heath System Research Symposium) in year 2 of the award. For planning purposes, it should be assumed that the...
meeting will be held in the Central Florida Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

- **Early Career Investigator Partnering Option:** Travel costs for the Initiating and Partnering PIs to present project information or disseminate project results at a DOD-sponsored meeting (e.g., progress review meeting, Military Heath System Research Symposium) in year 2 of the award. For planning purposes, it should be assumed that the meeting will be held in the Central Florida Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

For this award mechanism, direct costs may be requested for (not all-inclusive):

- Costs associated with data and research resource sharing (i.e., making a large dataset available to the public or developing an important resource for the scientific community).

- Travel in support of multidisciplinary collaborations.

- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel costs to scientific/technical meeting(s) is to present project information or disseminate project results from the FY21 TBIPHRP TRA.

- **Early Career Investigator Partnering Option:** Costs for the Initiating and Partnering PIs to travel to one scientific/technical meeting per year in addition to the required meeting described above. The intent of travel costs to scientific/technical meeting(s) is to present project information or disseminate project results from the FY21 TBIPHRP TRA.

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency’s procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

**II.D.6. Other Submission Requirements**

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.
II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

- To determine technical merit, all applications will be evaluated according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**
  
  - To what extent the relevance and applicability of the proposed research and anticipated findings adhere to the intent of the mechanism and at least one *sub-area within one of the three FY21 TBIPHRP TRA Focus Areas*.
  
  - How well the scientific rationale literature review, unpublished data, preliminary studies, and/or preclinical data support the development of the proposed project and provide the basis for the study questions and/or hypotheses.
  
  - To what extent stakeholder engagement was performed, and to what degree it helped formulate the project’s hypothesis/objective and research strategy, if applicable.
  
  - How well the purpose and objectives of the study, with detailed specific aims and hypotheses, are described and align with the tasks in the SOW.
  
  - To what extent the study design, methods, models, and analyses will meet the project’s goals and milestones.
  
  - How well the application acknowledges potential problem areas and pitfalls, and provides alternative approaches.
  
  - Whether the research is feasible and can be completed within the proposed period of performance.

*For studies performing animal research:*

- To what extent the choice of animal model is validated and well-justified in the literature.
  
  - How well the study explains how and why the animal species, strain, and model(s) being used can address the scientific objectives and the relevance to human biology.
  
  - How relevant the approaches are to validate or corroborate findings from animal studies to human data sources/populations.
  
  - If applicable, to what extent the proposed validation approaches or corroborative studies “de-risk” the possibility that the findings from the animal study cannot be translated into human populations.
○ To what extent the data reporting and documentation plan are appropriate to support a regulatory filing with the FDA or next stage of development, if applicable

For studies performing prospective human subject recruitment:

○ How well the application describes the scientific rationale for the proposed clinical research/trial and the endpoints to be measured.

○ For studies evaluating established intervention(s), whether the proposed intervention(s) has established efficacy in relevant clinical setting(s) and is significantly mature.

○ The degree to which the recruitment, screening, and retention processes for human subjects will meet the needs of the proposed study.

○ Whether the application demonstrates access to the proposed study population at each site.

○ How well the inclusion/exclusion criteria meet the needs of the proposed clinical research/trial.

○ How well the application identifies any potential barriers to accrual and provides mitigation plans for addressing unanticipated delays (e.g., slow accrual, attrition).

○ How well plans to collect specimens and conduct laboratory evaluations are relevant to the study objectives, if applicable.

○ To what degree the data collection instruments are appropriate to the proposed study.

• Statistical Plan and Data Analysis

○ As applicable, describe how the randomization and blinding procedures for the study are appropriate, and specify any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results are described.

○ If applicable, describe how the justification for not utilizing randomization and/or blinding is appropriate.

○ To what degree the statistical model and data analysis plan are suitable with respect to the study objectives.

○ How the statistical plan, including sample size projections and power analysis, is appropriate to meet the objectives of the study and all proposed correlative studies.

○ If applicable, whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.
If applicable, whether the plans for the valid analysis of group differences on the basis of sex/gender, race, and/or ethnicity for phase 3 clinical trials are appropriate for the proposed research.

**Ethical Considerations (for applications proposing prospective human subject recruitment)**

- Whether the population selected to participate in the study stands to benefit from the knowledge to be gained as a result of the proposed research.
- How the level of risk to human subjects is minimized and how the safety monitoring and reporting is appropriate for the level of risk.
- To what degree privacy and confidentiality of study records are appropriately considered.
- To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.
- Whether the strategy for the inclusion of women and minorities is appropriate to the objectives of the study.
- Whether the distribution of the proposed enrollment on the basis of sex/gender, race, and/or ethnicity is appropriate for the proposed research.

**Data and Research Resources Sharing Plan**

- How the data and resources generated during the performance of the project will be shared with the research community, including the sharing of de-identified data with data repositories, are described.
- As applicable, how thoroughly the application identifies and describes the intended NINDS TBI and/or PhenX CDEs to be used.
- If applicable, how thoroughly the application justifies any instances where existing CDEs are not applicable or appropriate.

**Impact and Relevance to Military Health**

- To what degree the anticipated outcome(s) or knowledge/materiel product(s) that will make important scientific advances and improve the understanding, prevention, and/or treatment of TBI and/or psychological health conditions.
- To what extent the long-range vision of the proposed research will impact the field of study and/or the lives of relevant patient or community populations.
- If applicable, to what degree the proposed materiel or knowledge product represents an improvement to currently available pharmacologic agents, devices, or clinical practice guidance.
○ To what degree the proposed research will contribute to the implementation of evidence-based interventions, tools, policies, and guidelines (as applicable).

○ To what degree the study identifies potential issues that might limit the impact of the proposed research and provides strategies that may be employed to overcome those issues.

○ If applicable, to what extent the proposed research will be able to enhance readiness and recovery in the battlefield, training, or resource limited environments.

• **Transition Plan**

○ Whether the outcomes expected upon completion of the proposed research are relevant, measurable, and include the intended end-user.

○ Whether the funding strategy described to bring the intervention to the phase of development and/or delivery to market or incorporation into patient care (e.g., specific industry partners, specific funding opportunities) is reasonable and achievable.

○ Whether the proposed collaborations and other resources are appropriate to provide continuity of development.

○ Whether the schedule and milestones for bringing the intervention to the next level of development (next-phase clinical trials, transition to industry, delivery to the market, incorporation into clinical practice, and/or approval by the FDA) are achievable.

○ How well the application identifies intellectual property ownership, describes an appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on product development and subsequent government access to products supported by this program announcement.

○ If applicable, how well-developed the risk analysis is for cost, schedule, manufacturability, and sustainability.

• **Personnel**

○ To what degree the research team’s background and experience/expertise are appropriate to accomplish the proposed work.

○ If applicable, to what extent the study team composition is able to provide military-relevant subject matter expertise to the proposed research.

○ Whether the levels of effort by the PI and other key personnel are appropriate to ensuring the success of the project.
If applicable, to what extent the CBPR Letter(s) of Commitment describe the role and commitment of the lived experience consultant(s) or community-based partner(s) on the research team.

If applicable, how well the CBPR approach that will be used (e.g., LEC, partner organization, CAB, co-researcher model) and at what points CBPR will be employed in the study are described.

• Partnership Statement (only applicable to Early-Career Investigator Partnering Option applications)
  ○ Whether the Early-Career Investigator meets the eligibility requirements.
  ○ To what degree the partnership and combined experience/expertise of the both PIs are critical to the research strategy and completion of the SOW.
  ○ To what degree the partnership will better address the research question together rather than through separate individual efforts.
  ○ How well the application reflects that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project.
  ○ Whether funding will be balanced between both PIs or is otherwise warranted and clearly justified.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• Budget
  ○ Whether the direct costs exceed the allowable direct costs as published in the program announcement.
  ○ Whether the budget is appropriate for the proposed research.

• Environment
  ○ To what degree the scientific environment and the accessibility of institutional/organizational resources support the proposed research.
  ○ Whether the quality and extent of institutional support are appropriate for the proposed project.

• Application Presentation
  ○ To what extent the writing, clarity, and presentation of the application components influence the review.
II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY21 TBIPHRP, as evidenced by the following:
  - Adherence to the intent of the award mechanism
  - Program portfolio composition
  - Relative impact and relevance to military health

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is programmatic review, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section II.E.1.b, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at https://cdmrp.army.mil/about/2tierRevProcess. An information paper describing the funding recommendations and review process for the award mechanisms for the FY21 TBIPHRP will be provided to the PI(s) and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.88, over the period of performance, the
The federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant’s integrity, business ethics, and record of performance under federal awards when determining a recipient’s qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in Section I, Overview of the Funding Opportunity.

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY21 funds are anticipated to be made no later than September 30, 2022. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI’s organization.

Pre-Award Costs: An institution of higher education, hospital, or other non-profit organization may, at its own risk and without the government’s prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions with any other individual. The award document signed by the Grants Officer is the official authorizing document.

Federal Government Organizations: Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental
Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Changes in PI, Initiating PI, or Partnering PI will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

The organizational transfer of an award supporting a clinical research/trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award supporting the PI, Initiating PI, or Partnering PI is discouraged and will be evaluated on a case-by-case basis and only allowed at the discretion of the Grants Officer.

Changes in PI are discouraged, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest DoD R&D General Terms and Conditions; the USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions; and the USAMRAA General Research Terms and Conditions with For-Profit Organizations for further information.
II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. **If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.**

Annual progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

Annual quad charts will be required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline if and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

Inclusion Enrollment Reporting Requirement (only required for clinical research studies): Enrollment on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final technical report. The suggested Inclusion Enrollment Report format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP.

Awards resulting from the FY21 TBIPHRP TRA will incorporate additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. Recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. CDMRP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP
should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507  
Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035  
Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 605a. The program announcement numeric version code will match the General Application Instructions version code 605.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
• Project Narrative exceeds page limit.
• Project Narrative is missing.
• Budget is missing.

For applications involving animal research:
• Attachment 7, Animal Research Plan, is missing.

For applications recruiting human subjects:
• Attachment 8, Clinical Strategy Statement, is missing.
• Attachment 9, Data Management, is missing.
• Attachment 10, Questionnaires and Other Research Data Collection Instruments, is missing.

II.H.2.b. Modification
• Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
• Documents not requested will be removed.

II.H.2.c. Withdrawal
The following may result in administrative withdrawal of the pre-application or application:
• An FY21 TBIPHRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. A list of the FY21 TBIPHRP Programmatic Panel members can be found at https://cdmrp.army.mil/tbiphrp/panels/panels21.
• The application fails to conform to this program announcement description.
• Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
• To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY21, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (https://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies may be administratively withdrawn.
• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.

• Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.

• Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.

• Submission of the same research project to different funding opportunities within the same program and fiscal year.

• The invited application proposes a different research project than that described in the pre-application.

• The PI(s) do not meet the eligibility criteria.

• The application proposes a clinical trial for a new intervention or a new indication for products currently FDA-approved.

• **Early-Career Investigator Partnering Option:** Failure to submit both (Initiating and Partnering PI) applications by the deadline.

• Application failed to address at least one sub-area within one of the three FY21 TBIPHRP TRA Focus Areas.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.
### II.H.3. Application Submission Checklist

<table>
<thead>
<tr>
<th>Application Components</th>
<th>Action</th>
<th>Single or Initiating PI Completed</th>
<th>Partnering PI Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 Research &amp; Related Application for Federal Assistance (extramural submissions only)</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)</td>
<td>Complete tabs as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attachments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impact and Relevance to Military Health Statement: Upload as Attachment 6 with file name “Impact.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Research Plan: Upload as Attachment 7 with file name “AnimRschPln.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Strategy Statement: Upload as Attachment 8 with file name “Clinical.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data Management: Upload as Attachment 9 with file name “Data_Manage.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaires and Other Research Data Collection Instruments: Upload as Attachment 10 with file name “Data_Collection.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition Plan: Upload as Attachment 11 with file name “Transition.pdf”</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partnership Statement: Upload as Attachment 12 with file name “Partnership.pdf” if applicable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Components</td>
<td>Action</td>
<td>Single or Initiating PI Completed</td>
<td>Partnering PI Completed</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Research &amp; Related Personal Data</td>
<td>Representations (extramural submissions only): Upload as Attachment 13 with file name “RequiredReps.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 14 with file name “MFBudget.pdf” if applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Complete form as instructed. Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (intramural submissions only)</td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (extramural submissions only)</td>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget (intramural submissions only)</td>
<td>Complete the Suggested DOD Military Budget Format, including justification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX 1: ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACOS/R&amp;D</td>
<td>Associate Chief of Staff for Research and Development</td>
</tr>
<tr>
<td>ACURO</td>
<td>Animal Care and Use Review Office</td>
</tr>
<tr>
<td>AdjDs</td>
<td>Adjustment Disorders</td>
</tr>
<tr>
<td>ASRs</td>
<td>Acute Stress Reactions</td>
</tr>
<tr>
<td>ARRIVE</td>
<td>Animal Research: Reporting In Vivo Experiments</td>
</tr>
<tr>
<td>B</td>
<td>Billion</td>
</tr>
<tr>
<td>CAB</td>
<td>Community Advisory Board</td>
</tr>
<tr>
<td>CBPR</td>
<td>Community-Based Participatory Research</td>
</tr>
<tr>
<td>CDE</td>
<td>Common Data Element</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>DHP</td>
<td>Defense Health Program</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DoDGARs</td>
<td>Department of Defense Grant and Agreement Regulations</td>
</tr>
<tr>
<td>DUNS</td>
<td>Data Universal Numbering System</td>
</tr>
<tr>
<td>eBRAP</td>
<td>Electronic Biomedical Research Application Portal</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>EFIC</td>
<td>Exception From Informed Consent</td>
</tr>
<tr>
<td>ET</td>
<td>Eastern Time</td>
</tr>
<tr>
<td>FAD</td>
<td>Funding Authorization Document</td>
</tr>
<tr>
<td>FAPIIS</td>
<td>Federal Awardee Performance and Integrity Information System</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FITBIR</td>
<td>Federal Interagency Traumatic Brain Injury Research</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GUID</td>
<td>Global Unique Identifier</td>
</tr>
<tr>
<td>HIPAA</td>
<td>Health Insurance Portability and Accountability Act</td>
</tr>
<tr>
<td>HRPO</td>
<td>Human Research Protection Office</td>
</tr>
<tr>
<td>IACUC</td>
<td>Institutional Animal Care and Use Committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>LEC</td>
<td>Lived Experience Consultation</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MIPR</td>
<td>Military Interdepartmental Purchase Request</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NINDS</td>
<td>National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td>NPC</td>
<td>Non-Profit Corporation</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NRAP</td>
<td>National Research Action Plan</td>
</tr>
<tr>
<td>ORCID</td>
<td>Open Researcher and Contributor ID, Inc.</td>
</tr>
<tr>
<td>ORP</td>
<td>Office of Research Protections</td>
</tr>
<tr>
<td>PH/TBIRP</td>
<td>Psychological Health and Traumatic Brain Injury Research Program</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PII</td>
<td>Personally Identifiable Information</td>
</tr>
<tr>
<td>PTSD</td>
<td>Posttraumatic Stress Disorder</td>
</tr>
<tr>
<td>SAM</td>
<td>System for Award Management</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>STEM</td>
<td>Science, Technology, Engineering, and/or Mathematics</td>
</tr>
<tr>
<td>TBI</td>
<td>Traumatic Brain Injury</td>
</tr>
<tr>
<td>TBIPHRP</td>
<td>Traumatic Brain Injury and Psychological Health Research Program</td>
</tr>
<tr>
<td>TRA</td>
<td>Translational Research Award</td>
</tr>
<tr>
<td>UDE</td>
<td>Unique Data Element</td>
</tr>
<tr>
<td>UEI</td>
<td>Unique Entity Identifier</td>
</tr>
<tr>
<td>URL</td>
<td>Uniform Resource Locator</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>U.S. Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRDC</td>
<td>U.S. Army Medical Research and Development Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>VA</td>
<td>Department of Veterans Affairs</td>
</tr>
</tbody>
</table>
APPENDIX 2: DOD AND VA WEBSITES

PIs are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. Below is a list of websites that may be useful in identifying additional information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration.

Air Force Office of Scientific Research
https://www.wpafb.af.mil/afrl/afosr/

Air Force Research Laboratory
https://www.wpafb.af.mil/afrl

Armed Forces Radiobiology Research Institute
https://afrri.usuhs.edu/home

Combat Casualty Care Research Program
https://ccc.amedd.army.mil

Congressionally Directed Medical Research Programs
https://edmrp.army.mil

Defense Advanced Research Projects Agency
https://www.darpa.mil/

Defense Health Agency
https://health.mil/dha

Defense Suicide Prevention Office
https://www.dspo.mil/

Defense Technical Information Center
https://www.dtic.mil

Defense Threat Reduction Agency
https://www.dtra.mil/

Military Health System Research Symposium
https://mhsrs.amedd.army.mil/SitePages/Home.aspx

Military Infectious Diseases Research Program
https://midrp.amedd.army.mil

Military Operational Medicine Research Program
https://momrp.amedd.army.mil

Naval Health Research Center
https://www.med.navy.mil/Naval-Medical-Research-Center/Naval-Health-Research-Center/

Navy Bureau of Medicine and Surgery
https://www.med.navy.mil/

Navy and Marine Corps Public Health Center

Naval Medical Research Center
https://www.med.navy.mil/Naval-Medical-Research-Center/

Office of Naval Research
https://www.onr.navy.mil/

Office of the Under Secretary of Defense for Acquisition, Technology and Logistics
https://www.acq.osd.mil/

Psychological Health Center of Excellence
https://health.mil/Military-Health-Topics/Centers-of-Excellence/Psychological-Health-Center-of-Excellence

Telemedicine and Advanced Technology Research Center
https://www.tatrc.org/

Traumatic Brain Injury Center of Excellence

Uniformed Services University of the Health Sciences
https://www.usuhs.edu/research

U.S. Air Force 59th Medical Wing
https://www.59mdw.af.mil/

U.S. Army Aeromedical Research Laboratory
https://www.usaarl.army.mil/
U.S. Army Combat Capabilities Development Command
https://www.army.mil/ccdc

U.S. Army Institute of Surgical Research
https://usaisr.amedd.army.mil

U.S. Army Medical Materiel Development Activity
https://www.usammda.army.mil/

U.S. Army Medical Research and Development Command
https://mrdc.amedd.army.mil/

U.S. Army Medical Research Institute of Infectious Diseases
https://www.usamriid.army.mil/

U.S. Army Research Institute of Environmental Medicine
https://www.usariem.army.mil/

U.S. Army Research Laboratory
https://www.arl.army.mil

U.S. Army Sharp, Ready and Resilient Directorate

U.S. Department of Defense Blast Injury Research Program
https://blastinjuryresearch.amedd.army.mil/

U.S. Department of Defense Sexual Assault Prevention and Response Office
https://www.sapr.mil

U.S. Department of Veterans Affairs, Office of Research and Development
https://www.research.va.gov

U.S. Naval Research Laboratory
https://www.nrl.navy.mil

Walter Reed Army Institute of Research
https://www.wrair.army.mil
APPENDIX 3: SAMPLE FITBIR CONSENT LANGUAGE

Data from this study may be submitted to the Federal Interagency Traumatic Brain Injury (FITBIR) informatics system. FITBIR is a computer system run by the National Institutes of Health that allows researchers studying traumatic brain injury to collect and share information with each other. With an easier way to share, researchers hope to learn new and important things about traumatic brain injury more quickly than before.

During and after the study, the researchers will send information about you or your child’s health and behavior and in some cases, you or your child’s genetic information, to FITBIR. However, before they send it to FITBIR, they will remove information such as name, date of birth, and city of birth, and replace that information with a code number. Other researchers nationwide can then file an application to obtain access to your study data for research purposes. Experts who know how to protect health and science information will look at every request carefully to minimize risks to your privacy.

You or your child may not benefit directly from allowing your information to be shared with FITBIR. The information provided to FITBIR might help researchers around the world treat future children and adults with traumatic brain injury so that they have better outcomes. FITBIR will report on its website about the different studies that researchers are conducting using FITBIR data; however, FITBIR will not be able to contact you or your child individually about specific studies.

You may decide now or later that you do not want to share you or your child’s information using FITBIR. If so, contact the researchers who conducted this study, and they will tell FITBIR, which can stop sharing the research information. However, FITBIR cannot take back information that was shared before you changed your mind. If you would like more information about FITBIR, this is available on-line at http://fitbir.nih.gov.

Language to be used to describe certificates of confidentiality (three versions):

1. Language for new studies that will be consenting subjects for the first time or for ongoing studies that will be re-consenting subjects because they are applying for a Certificate of Confidentiality for the study

   To help protect you and/or your child’s privacy the investigators of this study [have applied for]/[have obtained] a Certificate of Confidentiality from the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government.

   With this Certificate, we, the investigators, cannot be forced (e.g., by court subpoena) to disclose information that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. Be aware that disclosure of you and/or your child’s identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

   You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from voluntarily releasing information about your child, yourself, or your involvement in this research. Note, however, that if an insurer or employer learns about you and/or your child’s participation, and obtains your consent to receive research information, then
the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

We are also asking your consent to provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository, created by the Department of Defense and the National Institutes of Health to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injuries.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by qualified researchers only. Data provided to FITBIR as part of you and/or your child’s participation in this research study will be de-identified—i.e., you and/or your child’s name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized “Certificate of Confidentiality” that will help FITBIR and participating institutions avoid being forced to disclose information that may identify you as a FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you, your child, or others. With respect to you and/or your child’s participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

2. Language for studies that already have a Certificate and will be re-consenting subjects about FITBIR

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and National Institutes of Health (NIH)—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you and/or your child’s participation in this research study will be de-identified—i.e., you and/or your child’s name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized “Certificate of Confidentiality” to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. Be aware that disclosure of you and/or your child’s identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

As you know, we have obtained a Certificate of Confidentiality from NIH that enables us to keep the individually identifiable information that you provide as a research subject private. With this Certificate, we, the investigators cannot be forced to disclose research information collected in
this study that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. This protection will continue to protect you and/or your child’s privacy even though we are providing de-identified data to FITBIR.

You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from voluntarily releasing information about your child, yourself, or your involvement in this research. Note, however, that if an insurer or employer learns about you and/or your child’s participation and obtains your consent to receive research information, then the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

Finally, as we explained when we told you about this privacy protection before, we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you and/or your child or others based on information they learn during this study. With respect to you and/or your child’s participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

3. Language for studies without a Certificate of their own

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and the National Institutes of Health (NIH)—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you or your child’s participation in this research study will be de-identified—i.e., you and/or your child’s name will be separated from the data. However, since this institution and others submitting data to FITBIR will still retain individually identifying information related to the data provided, the NIH has issued a legislatively authorized “Certificate of Confidentiality” to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are also permitted to make voluntary disclosures with respect to information that is submitted to FITBIR, but do not plan to do so except in the event of severe threats to public health or safety. If, as part of your participation in this research study itself, we learn about serious harm to you, your child or someone else, we would take steps to prevent that harm including notifying appropriate authorities like the police or child welfare.